Legal

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

GLP-1s are in high demand from patients, and the results are often impressive. But are there hidden risks in prescribing these drugs?

How to safeguard the benefits of private practice.

Tariffs will likely result in rising costs and supply chain disruptions that will reshape the economic outlook for the global economy — and your business too.

The time is now to create an action plan that fits your practice when it comes to cutting costs and raising revenue streams. Read Medical Economics Insider to get started.

In many states, nurse practitioners are gaining greater permission to practice and prescribe independently, with varying levels of physician oversight. What do physicians think of this trend? See our exclusive physician survey results to find out.

Introducing the inaugural issue of Medical Economics Insider, featuring practical tips and expert interviews on medical practice finance, plus exclusive survey data on how physicians feel about nurse practitioner independence.

Andrea Greco, SVP of health care safety at CENTEGIX, sat down with Medical Economics for an exclusive Q&A.

Coming March 31 to MedicalEconomics.com.

Andrea Greco, SVP of healthcare safety at CENTEGIX, discusses risk assessments in medical practices.

Andrea Greco, SVP of healthcare safety at CENTEGIX, details one key change to improve practice safety.

Study warns that artificial intelligence could increase legal risk and burnout if health systems fail to support doctors.

People who requested genetic tests were customers, not patients, so legal protection may be limited.

Andrea Greco, SVP of healthcare safety at CENTEGIX, details cost-effective options for smaller practices looking to conduct risk assessments.

As business and administrative challenges continue to mount — from declining reimbursement rates to increased competition — our mission is to deliver timely content that helps you run your practice more effectively. Enter Medical Economics Insider.

Andrea Greco, SVP of healthcare safety at CENTEGIX, talks about possible next steps once risks are identified.

Andrea Greco, SVP of Healthcare Safety at CENTEGIX, breaks down the key legal and regulatory factors medical practices must consider when conducting risk assessments.

Andrea Greco, SVP of healthcare safety at CENTEGIX, identifies common shortcomings of risk assessments and explains how practices can address their blind spots.

Andrea Greco, SVP of healthcare safety at CENTEGIX, talks about common risk assessment tools.

Andrea Greco, SVP of healthcare safety at CENTEGIX, explains when medical practices should conduct risk assessments.

Andrea Greco, SVP of healthcare safety at CENTEGIX, explains why risk assessments are so important for medical practices.

Andrea Greco, SVP of healthcare safety at CENTEGIX, discusses risk assessments in medical practices.